Edition:
United Kingdom

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

18.43USD
15 Feb 2019
Change (% chg)

$-0.05 (-0.27%)
Prev Close
$18.48
Open
$18.40
Day's High
$18.58
Day's Low
$17.77
Volume
172,456
Avg. Vol
142,501
52-wk High
$34.98
52-wk Low
$12.56

Latest Key Developments (Source: Significant Developments)

CytomX Therapeutics CEO Appointed To Additional Role Of Chairman
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS.CEO SEAN MCCARTHY APPOINTED TO ADDITIONAL ROLE OF CHAIRMAN.BOARD CHAIRMAN HOYOUNG HUH WILL RETIRE FROM BOARD EFFECTIVE DECEMBER 31, 2018.  Full Article

Cytomx Therapeutics Inc - QTRLY Net Loss Per Share $0.35
Wednesday, 8 Aug 2018 

CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 REVENUE $21.3 MILLION VERSUS I/B/E/S VIEW $19.2 MILLION.QTRLY NET LOSS PER SHARE $0.35.Q2 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.  Full Article

Cytomx Therapeutics Says Public Offering Of 5.10 Mln Common Shares Priced At $24.50/ Share
Friday, 13 Jul 2018 

July 12 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 5.10 MILLION COMMON SHARES PRICED AT $24.50PER SHARE.  Full Article

CytomX Therapeutics Announces Proposed Public Offering Of Common Stock
Tuesday, 10 Jul 2018 

July 10 (Reuters) - CytomX Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CYTOMX THERAPEUTICS INC - HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $125 MILLION OF SHARES OF ITS COMMON STOCK.CYTOMX THERAPEUTICS - EXPECTS TO GRANT UNDERWRITERS 30-DAY OPTION TO PURCHASE UP TO ADDITIONAL $18.75 MILLION OF SHARES OF STOCK AT PUBLIC OFFERING PRICE.CYTOMX THERAPEUTICS - EXPECTS TO USE PROCEEDS FROM OFFERING TO DEVELOP ITS PROPRIETARY PROBODY THERAPEUTIC PIPELINE & TO ADVANCE ADDITIONAL PROGRAMS.  Full Article

Perceptive Advisors LLC Reports 5.6 Pct Passive Stake In CytomX Therapeutics As On Dec 8
Monday, 18 Dec 2017 

Dec 18 (Reuters) - CytomX Therapeutics Inc ::PERCEPTIVE ADVISORS LLC REPORTS 5.6 PERCENT PASSIVE STAKE IN CYTOMX THERAPEUTICS INC AS ON DEC 8 - SEC FILING.  Full Article

Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC.CYTOMX THERAPEUTICS INC - ‍IND ACCEPTANCE RESULTS IN A $10 MILLION MILESTONE PAYMENT TO CYTOMX​.CYTOMX THERAPEUTICS INC - ‍BRISTOL-MYERS SQUIBB HAS RECEIVED ACCEPTANCE OF IND FROM U.S. FDA FOR A CTLA-4-DIRECTED PROBODY THERAPEUTIC​.  Full Article

CytomX reports Q3 loss per share $‍0.28​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - CytomX Therapeutics Inc :CytomX announces third quarter 2017 financial results and operational progress.Q3 revenue $24.1 million versus $3.5 million.Q3 revenue view $17.5 million -- Thomson Reuters I/B/E/S.CytomX Therapeutics Inc qtrly loss per share $‍0.28​.  Full Article